• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Nanoparticle-Mediated Lipid Metabolic Reprogramming of T Cells in Tumor Microenvironments for Immunometabolic Therapy

    2021-01-18 07:23:58DongyoonKimYinaWuQiaoyunLiYuKyoungOh
    Nano-Micro Letters 2021年2期

    Dongyoon Kim, Yina Wu, Qiaoyun Li, Yu-Kyoung Oh

    ABSTRACT We report the activation of anticancer effector functions of T cells through nanoparticle-induced lipid metabolic reprogramming. Fenofibrate was encapsulated in amphiphilic polygamma glutamic acid-based nanoparticles (F/ANs), and the surfaces of F/ANs were modified with an anti-CD3e f(ab′)2 fragment, yielding aCD3/F/ANs. An in vitro study reveals enhanced delivery of aCD3/F/ANs to T cells compared with plain F/ANs. aCD3/F/AN-treated T cells exhibited clear mitochondrial cristae, a higher membrane potential, and a greater mitochondrial oxygen consumption rate under glucose-deficient conditions compared with T cells treated with other nanoparticle preparations. Peroxisome proliferatoractivated receptor-α and downstream fatty acid metabolismrelated genes are expressed to a greater extent in aCD3/F/AN-treated T cells. Activation of fatty acid metabolism by aCD3/F/ANs supports the proliferation of T cells in a glucose-deficient environment mimicking the tumor microenvironment. Real-time video recordings show that aCD3/F/AN-treated T cells exerted an effector killing effect against B16F10 melanoma cells. In vivo administration of aCD3/F/ANs can increase infiltration of T cells into tumor tissues. The treatment of tumor-bearing mice with aCD3/F/ANs enhances production of various cytokines in tumor tissues and prevented tumor growth. Our findings suggest the potential of nanotechnology-enabled reprogramming of lipid metabolism in T cells as a new modality of immunometabolic therapy.

    KEYWORDS Metabolic reprogramming; T cells; Fatty acid metabolism; Immunometabolic therapy; Mitochondrial function

    1 Introduction

    Anticancer chemicals and biologic necrosis factors have been delivered to tumors using various nanoparticles [1—4]. To date, the most studied anticancer nanomedicines for delivery of anticancer agents are those containing tumortargeting ligands. Despite progress in nano-enabled targeted delivery of anticancer therapeutics to tumor tissues, clinical translation of these nanomedicines remains limited. One reason for the limited clinical translation of ligand-modified nanomedicines is the heterogeneity of tumors. The responsiveness of tumor cells to anticancer drugs can differ depending on tumor type. Moreover, the delivery of anticancer drugs to nonresponsive tumor cells can exert variable effects depending on the physiological properties of the cells [5, 6]. Even in drug-responsive tumor types, differing densities of target receptors on tumor cells can variably affect the extent of delivery of therapeutics to cancer cells [7]. Folate receptors and transferrin receptors have long been studied for targeted delivery of anticancer drugs to tumor cells. However, the density of these receptors on tumor cells varies such that delivery of nanoparticle anticancer drugs to tumor cells with a lower density of target receptors may be insufficient [8].

    An emerging approach for circumventing this tumor cell heterogeneity focuses on leveraging tumor-adjacent immune cells in the tumor microenvironment [9, 10]. Compared with tumor cells, adjacent cells in the tumor microenvironments are reported to be less heterogeneous [11]. Reported targets in the microenvironment of various tumors include fibroblast activation protein, expressed on cancer-associated fibroblasts [12]; CD11c, expressed on dendritic cells [13]; and CD3, a biomarker of T cells whose expression on T cells is reported to be preserved in various tumors [14]. Exploiting this reduced heterogeneity of tumor-adjacent cells, we recently reported activation of cancer-associated fibroblasts for enhanced delivery of doxorubicin in graphene-based nanosheets [15]. It has been reported that dendritic cells in the tumor microenvironment can be activated by immune adjuvant-loaded polydopamine nanoparticles [16] and other nanoparticles, such as polymeric nanoparticles [17]. A number of studies addressing modulation of the tumor microenvironment have reported enhanced infiltration of T cells. However, the recruited T cells have been reported to lose their activity in the hypoglycemic tumor microenvironment [18]. Thus, there exists an unmet need for a therapeutic strategy for activating effector functions of T cells in the tumor microenvironment.

    The importance of manipulating metabolic imbalances in immune cells in anticancer immunotherapy has become increasingly apparent [19]. Effector cytotoxic T cells have been reported to lose their activity because of the metabolically stressful conditions of the tumor microenvironment [20]. Glucose is known to be deficient in the tumor microenvironment, and the cytotoxic activity of T cells is impaired by a lack of energy. Thus, metabolic reprogramming of immune cells in the tumor microenvironment to allow utilization of different energy substrates would be a viable strategy for improving immunotherapy.

    In this study, we tested the hypothesis that metabolic reprogramming of T cells using a nanotechnology approach could activate T cells to fight against tumor cells (Fig. 1). To this end, we designed T cell-targeting nanoparticles encapsulating the lipid metabolism-activating drug molecule, fenofibrate, which is known to induce the expression of peroxisome proliferator-activated receptor (PPAR)-α and downstream fatty acid metabolism-related genes. It has been reported that promoting fatty acid metabolism by orally administered PPAR-α agonist can relieve metabolic stress from hypoglycemic condition in tumor microenvironment and preserve effector function of T cells, thereby enhancing anti PD-1 immunotherapy [21]. For T cell-targeted delivery, we entrapped fenofibrate in amphiphilic poly (γ-glutamic acid)-based nanoparticles (F/ANs) and further modified the nanoparticle surface with an anti-CD3e f(ab′)2 fragment, yielding aCD3/F/ANs. Here, we report that aCD3/F/ANs activate fatty acid metabolism and mitochondrial functions and stimulate the anticancer activity of T cells in tumor microenvironments.

    2 Experimental Section

    2.1 Synthesis of Amphiphilic Poly (γ-Glutamic Acid)

    Amphiphilic poly (γ-glutamic acid) (AP) was synthesized by grafting phenylalanine ethyl ester with poly (γ-glutamic acid) (γ-PGA) through a carbodiimide crosslinking reaction, as described previously [22]. Briefly, 5.94 μmol of γ-PGA (50 kDa; BioLeaders, Daejeon, Republic of Korea) was dissolved in 30 mL of 0.3 M NaHCO3solution followed by addition of 2.84 mmol of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC; Tokyo Chemical Industry Co., Ltd., Tokyo, Japan) with stirring on ice for 30 min. Next, 2.30 mmol of L-phenylalanine ethyl ester hydrochloride (Sigma-Aldrich, St. Louis, MO, USA) was added and the solution was stirred for an additional 24 h at 37 °C. For imaging and confocal microscopy, fluorescent dye-labeled AP (fAP) was synthesized by adding 3.2 μmol of fluoresceinyl glycine amide (5-(aminoacetamido) fluorescein) (Thermo-Fisher Scientific, Waltham, MA, USA) to a solution containing 2 μmol of γ-PGA, 0.96 mmol of EDC and 0.77 mmol of L-phenylalanine ethyl ester hydrochloride and allowing the reaction to proceed for 24 h. The resulting AP and fAP were purified by dialyzing first in triple distilled water for 48 h and then in methanol for 48 h using a Spectra/Pore dialysis membrane (MWCO, 3 kDa; Spectrum Labs, Rancho Dominguez, CA, USA), after which they were lyophilized and stored at 4 °C until use. The synthesis of AP was confirmed by1H NMR spectroscopy.

    2.2 Preparation of Fenofibrate-Loaded and Anti-CD3 Antibody-Modified Nanoparticles

    Fig. 1 Metabolic reprogramming of T cells by aCD3/F/ANs. a Schematic illustration of the aCD3/F/AN preparation process. b Mechanism by which aCD3/F/ANs increase mitochondrial fatty acid metabolism in T cells. c Proposed effect of fatty acid metabolism reprogramming on T cell-mediated killing of cancer cells

    Fenofibrate was encapsulated in AP-based nanoparticles (ANs) or in fAP-based nanoparticles (fANs) using a thin film hydration method. In brief, 0.55 μmol of fenofibrate (Sigma-Aldrich) in 1 mL methanol was added into 1 mL of 0.1 mM AP or fAP in methanol solution. After solvent removal using a rotary evaporator (CCA-1110; Tokyo Rikakikai, Tokyo, Japan), the resulting film was hydrated with 1 mL of phosphate-buffered saline (PBS; pH 7.4) and sonicated for 10 min. The resulting F/ANs or fenofibrate-loaded fANs (F/ANs) were purified from unencapsulated fenofibrate by centrifugation at 12,000×g for 3 min. For modification with anti-CD3 antibody, F/ANs (3.5 mg) or F/fANs (3.5 mg) were first mixed with 6.4 μmole of EDC, then reacted on ice for 5 min and allowed to stand at room temperature (RT) for an additional 5 min. A solution of anti-mouse CD3e f(ab′)2 antibody (Bio X Cell, West Lebanon, NH, USA, catalog #BE0001-1FAB, lot #659618A1) was added to the EDC-activated F/AN suspension at a 1:50 molar ratio of antibody to AP and stirred at RT for 6 h. Free antibody was removed by dialysis (MWCO, 300 kDa; Spectrum Labs), and after quantifying the amount of antibody on the nanoparticle surface by BCA assay (Thermo-Fisher Scientific), aCD3/F/ANs or anti-mouse CD3e f(ab′)2 antibody-conjugated F/fANs (aCD3/F/fANs) were concentrated from reactants using an Amicon filter (Merck, Kenilworth, NJ, USA). In some experiments, anti-mouse CD3e f(ab′)2 antibody was conjugated to plain ANs (aCD3/ANs) or to fANs (aCD3/fANs). Physical mixture of equivalent amount of anti-mouse CD3e f(ab′)2 antibody with F/ANs (aCD3 + F/ANs) or with F/fANs (aCD3 + F/fANs) were used as control groups.

    2.3 Quantification of Encapsulated Fenofibrate

    The amount of fenofibrate encapsulated in ANs was analyzed by high-performance liquid chromatography (HPLC) using a Hewlett Packard model 1100 system (Hewlett Packard, Palo Alto, CA, USA) equipped with a reverse-phase C18 HPLC column (Nucleosil 100-5 C18; Macherey—Nagel, Düren, Germany). Lyophilized nanoparticles were dissolved in 200 μL of MeOH and injected into the C18 column. The column (temperature, 40 °C) was eluted using a mobile phase consisting of acetonitrile:water (pH of water adjusted to 4 with acetic acid) (90:10, v/v) at a flow rate of 1 ml/min. The peak of fenofibrate was monitored by measuring absorbance at 287 nm using at UV detector. Fenofibrate concentration was determined by reference to a standard curve prepared using a series of fenofibrate solutions in methanol.

    2.4 Characterization and Stability Studies

    Nanoparticles were characterized by size, surface charge, morphology, and elemental composition. The size distribution and zeta potential of nanoparticles were measured by dynamic light scattering (DLS) using an ELSZ-1000 instrument (Otsuka Electronics Co., Osaka, Japan). The morphology of nanoparticles was visualized by transmission electron microscopy (TEM) using a JEM1010 transmission electron microscope (JEOL, Tokyo, Japan). The presence of elemental oxygen, chlorine and sulfur in nanoparticles was determined by energy-dispersive X-ray spectroscopy (EDS-STEM) using a JEM-2100 F transmission electron microscope (JEOL). The stability of nanoparticles was monitored for up to 7 days. F/ANs and aCD3/F/ANs were stored in PBS at 4 °C. The sizes of particles were measured daily by DLS using an ELSZ-1000 instrument (Otsuka Electronics Co.).

    2.5 In Vitro Study of pH-Dependent Release

    The pH dependence of fenofibrate release from ANs was tested using a dialysis approach. Fenofibrate released from ANs was quantified by immersing a dialysis bag (MWCO, 3.5 kDa; Spectrum Labs) containing aCD3/F/ANs in 15 mL PBS containing 0.1% (w/v) Tween-80 (Sigma-Aldrich) at different pH values. At each time point, 1 mL of dialysis buffer was collected and the volume of dialysis was maintained by adding fresh buffer. Collected samples were lyophilized and dissolved in 200 μL methanol, and the amount of fenofibrate release was analyzed by HPLC.

    2.6 Animals

    Five-week-old C57BL/6 mice were purchased from Raon Bio and maintained under standard pathogen-free conditions at the Animal Center for Pharmaceutical Research, Seoul National University. All animal experiments were performed according to the Guidelines for the Care and Use of Laboratory Animals of the Institute of Laboratory Animal Resources, Seoul National University (approval number, SNU-190417-15(E)).

    2.7 Evaluation of CD3 Expression

    The expression levels of CD3 were determined at various cells including murine lung fibroblast cell line MLg (Korean Cell Line Bank, Seoul, Republic of Korea), human lung fibroblast cell line MRC-5 (Korean Cell Line Bank), human embryonic kidney cell line 293 T (ATCC, Manassas, VA, USA), murine bone marrow-derived macrophages (BMDM), murine bone marrow-derived dendritic cells (BMDC), and T cells. BMDM and BMDC were differentiated from monocytes as previously described [16, 23]. T cells were isolated from spleens of C57BL/6 mice using nylon wool columns [24]. MLg, MRC-5, 293 T, BMDM, BMDC, and T cells were stained with FITC-conjugated anti-mouse CD3 antibody (BioLegend, San Diego, CA, USA; catalog #100203, lot #B263028) for 1 h. The expression of CD3 was evaluated by flow cytometry.

    2.8 In Vitro Study of Nanoparticle Uptake

    In vitro cellular uptake of nanoparticles was evaluated using flow cytometry and fluorescence microscopy. For flow cytometry, MLg, MRC-5, 293 T, BMDM, BMDC and T cells were seeded onto 24-well plates (SPL Life Sciences) at 1 × 106cells/well and treated with 2 mg mL-1of fluorescein isothiocyanate (FITC)-labeled various nanoparticles for 4 h. Cells were harvested, washed with PBS, and analyzed by flow cytometry. For fluorescence microscopy, T cells were seeded onto 24-well plates (1 × 106cells/well) and treated with 2 mg mL-1FITC-labeled nanoparticles for 4 h. After washing and resuspending cells in 100 μL PBS, cell suspensions were plated onto poly-L-lysine coverslips (Corning, New York, NY, USA) and allowed to completely attach (30 min). Cells were then fixed with 4% formaldehyde in PBS for 10 min, washed with PBS, and stained with DAPI (4′,6-diamidino-2-phenylindole, Sigma-Aldrich). The fluorescence of cells was observed using a confocal laserscanning microscope (LSM 5 Exciter; Carl Zeiss, Inc., Jena, Germany).

    2.9 In Vitro Cell Viability Study

    In vitro viability of cells was measured after treatment of nanoparticles. After treatment with various nanoparticles, T cells were suspended in RPMI medium containing 10% WST-1 reagent. After incubating for 2 h at 37 °C, absorbance of the medium at 430 nm was measured using a Multi-Reader (Molecular Devices, San Jose, CA, USA). The other adherent cells including MLg, MRC-5, 293 T, BMDM and BMDC were incubated with culture medium containing 10% MTT reagent. After incubating for 2 h at 37 °C, absorbance of medium at 570 nm was detected using a Multi-Reader (Molecular Devices).

    2.10 In Vitro Study of PPARα, CD36 and Fatty Acid Oxidation-Associated Gene Expression

    Expression levels of PPARα, CD36 and fatty acid oxidationassociated genes in T cells following treatment with nanoparticles were measured by reverse transcription-polymerase chain reaction (RT-PCR), flow cytometry and western blot. The fatty acid oxidation-associated genes and gene products measured included carnitine palmitoyltransferase 1B (CPT1B), acyl-CoA dehydrogenase medium chain (MCAD) and acyl-CoA dehydrogenase long chain (LCAD) [21, 25]. Isolated mouse T cells were seeded onto 24-well plates (1 × 106cells/well) and treated with various nanoparticle preparations containing 20 μM fenofibrate for 24 h. For RTPCR, total RNA was isolated from T cells using the TRIzol reagent (Invitrogen, Carlsbad, CA, USA). cDNA was synthesized from mRNA using an AccuPower RT PreMix (Bioneer, Daejeon, Republic of Korea). Quantitative realtime RT-PCR was performed using a LightCycler FastStart DNA Master SYBR Green I system (Roche, Basel, Switzerland). Primer sequences used in RT-PCR are listed in Table S1. For western blot, T cells were lysed with a commercial radioimmunoprecipitation assay lysis buffer (Rockland, Limerick, PA, USA) containing a cocktail of protease inhibitors (cOmplete?, Mini, EDTA-free Protease Inhibitor Cocktail, Sigma-Aldrich (Roche). The amounts of protein were quantified by BCA assay and boiled at 95 °C 10 min. As primary antibodies, anti-mouse CPT1B (Proteintech, Rosemont, IL, USA; catalog #22170—1-AP, lot #00048665), anti-mouse LCAD (Proteintech, catalog #17526-1-AP, lot #00051417), anti-mouse MCAD (Proteintech, catalog #55210-1-AP, lot #09000327) and anti-mouse β-actin (Cell signaling, Denver, MA, USA; catalog #8457, lot #6) were used. Horseradish peroxidase-linked anti-rabbit IgG (Cell signaling, catalog #7074, lot #28) was used as secondary antibody. Amersham ECL Prime Western Blotting detection reagent (GE Healthcare, Chicago, IL, USA) was used for signal detection.

    Expression levels of PPARα protein were assessed by flow cytometry. Briefly, T cells were seeded onto 24-well plates (1 × 106cells/well) and treated with various nanoparticle preparations containing 20 μM fenofibrate for 48 h. Cells were harvested, washed with PBS, and stained with FITCconjugated anti-mouse CD3 antibody (BioLegend) for 1 h. Cells were fixed and permeabilized using a transcription factor buffer set (BioLegend; catalog #424401) and incubated with Alexa Fluor 647-conjugated anti-mouse PPARα antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA; catalog #sc-398394, lot #H1017) for 1 h.

    Protein expression levels of the fatty acid translocase, CD36, were analyzed by flow cytometry. Briefly, T cells seeded onto a 24-well plate (1 × 106cells/well) were treated with various nanoparticle preparations containing 20 μM fenofibrate for 48 h and then stained with FITC-conjugated anti-mouse CD3 antibody and allophycocyanin (APC)-conjugated anti-mouse CD36 antibody (BioLegend; catalog #102611, lot #B270594) for 1 h.

    2.11 Assessment of Mitochondrial Activation

    Mitochondrial activation was evaluated based on morphology, membrane potential and oxygen consumption rate (OCR). T cells were seeded onto a 24-well plate (1 × 106cells/well) and stimulated with anti-CD3/CD28 antibodytethered Dynabeads (Thermo-Fisher Scientific) at a 1:1 ratio of T cells to beads in the presence of interleukin (IL)-2 (10 ng mL-1) for 48 h. After the removal of beads, T cells were treated with various nanoparticle preparations containing 20 μM fenofibrate in the presence of IL-2 (10 ng mL-1) for 48 h. Cells were then starved by incubating for 24 h in low-glucose medium (XF DMEM Base Medium) containing 0.5 mM XF glucose, 1 mM XF glutamine, 0.5 mM carnitine (Sigma-Aldrich), 1% fetal bovine serum (FBS) and 40 μM palmitate-bovine serum albumin (BSA; Seahorse Biosciences, Billerica, MA, USA). For TEM observation of mitochondrial morphology, T cells were fixed with Karnovsky’s solution and pelleted, after which cell pellets were fixed with 1% osmium tetroxide for 1 h and stained with 0.5% uranyl acetate overnight. Cell pellets were dehydrated with ethanol and sequentially immersed in ethanol/Spurr’s resin (1:1) solution and ethanol/Spurr’s (1:2) solution for 1 h each [26]. Cells were then incubated with Spurr’s resin again at 4 °C overnight, followed by incubation at 70 °C overnight. Thin sections (60 nm) were prepared and observed by TEM (Talos L120C; Thermo Fisher Scientific, Inc.).

    Mitochondrial membrane potential was measured by flow cytometry and confocal microscopy. For flow cytometry, cells were incubated with 0.125 μM MitoTracker Orange CMTMRos (Life Technologies) for 30 min and analyzed by flow cytometry. For confocal microscopy, cells were seeded onto poly-L-lysine coverslips after staining with MitoTracker. Nuclei were counterstained with DAPI and fixed with 4% formaldehyde. The fluorescence of T cells was observed by confocal laser-scanning microscopy (TCS8; Leica Microsystems GmbH, Wetzlar, Germany).

    OCR and extracellular acidification rate (ECAR) were measured with an XFp Extracellular Flux analyzer (Seahorse Biosciences) using an XFp Cell Mito Stress Test Kit (Seahorse Biosciences) and XFp Glycolysis Stress Kit (Seahorse Biosciences), according to the manufacturer’s instructions. For OCR measurements, T cells were seeded onto a Cell-Tak (Seahorse Biosciences) pre-coated XFp culture microplate (4 × 105cells/well). Immediately prior to OCR measurements, 100 μM of palmitate-BSA was added to the plate. During measurements, 2 μM oligomycin, 1.5 μM carbonyl cyanide-4 (trifluoromethoxy)phenyl hydrazone and 1 μM rotenone and antimycin A mixture were added to each well. For ECAR measurements, T cells were seeded onto a Cell-Tak pre-coated XFp microplate (4 × 105cells/well). During the measurement, 10 mM glucose, 1 μM oligomycin and 100 mM 2-deoxy-D-glucose were added to each well.

    2.12 In Vitro T Cell Proliferation Test

    The effect of nanoparticles on T cell proliferation was studied using cell apoptosis, cell proliferation, and live/dead cell assays. Mouse T cells were seeded onto a 24-well plate (1 × 106cells/well) and activated by adding anti-CD3/CD28 Dynabeads at a T cell:Dynabeads ratio of 1:1 in the presence of IL-2 (10 ng mL-1) for 48 h. After removing Dynabeads, T cells were treated with various nanoparticle preparations containing 20 μM fenofibrate for 48 h in the presence of IL-2 (10 ng mL-1). The medium was then changed to lowglucose medium supplemented with 40 μM palmitate-BSA and incubated for an additional 24 h.

    Apoptosis of T cells was measured using an Annexin V Apoptosis Detection Kit FITC (Thermo-Fisher Scientific). Apoptotic cells were detected by staining cells with annexin V and propidium iodide (PI). Cell viability was measured using WST-1 reagent (Sigma-Aldrich). In brief, T cells were suspended in 100 μL RPMI medium containing 10% WST-1 reagent and then seeded onto a 96-well plate. After incubating for 2 h at 37 °C, absorbance of the medium at 430 nm was measured using a Multi-Reader (Molecular Devices). For live/dead assays, T cells were harvested and stained with 2 μM calcein AM and 4 μM PI for 15 min. Cell viability was assessed by examining under a fluorescence microscope (DM IL; Leica).

    2.13 In Vitro Measurement of Lipid Uptake by T Cells

    Lipid uptake by T cells was measured by flow cytometry using fluorescently labeled lipids. T cells were seeded onto a 24-well plate (1 × 106cells/well) and stimulated with anti-CD3/CD28 antibody-tethered Dynabeads at a T cell to bead ratio of 1:1 in the presence of IL-2 (10 ng mL-1) for 48 h. Dynabeads were then removed, and T cells were further treated with various nanoparticle preparations containing 20 μM fenofibrate in the presence of IL-2 (10 ng mL-1) for 48 h. The medium was then replaced with fresh RPMI-1640 medium, and T cells were treated with 1 μM 4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-hexadecanoic acid (BODIPY C16, Thermo-Fisher Scientific), a fluorescent fatty acid, at 37 °C for an additional 2 h. T cells were harvested and washed with PBS, and lipid uptake was analyzed by flow cytometry.

    2.14 In Vitro Measurement of T Cell Secretion of Fatty Acid Metabolites

    Secretion of fatty acid metabolites from T cells was evaluated by assaying β-hydroxybutyrate in culture medium. Briefly, isolated T cells were seeded in a 24-well plate (1 × 106cells/well) and activated with anti-CD3/CD28 antibody-tethered Dynabeads at a T cell to bead ratio of 1:1 in the presence of IL-2 (10 ng mL-1) for 48 h. Dynabeads were removed, and T cells were treated with nanoparticle preparations containing 20 μM fenofibrate. After incubation with nanoparticles for an additional 48 h, cells were washed with PBS and resuspended in low-glucose medium with 40 μM palmitate-BSA. After starvation for 24 h, β-hydroxybutyrate concentration in the culture medium was measured using a β-Hydroxybutyrate Assay Kit (Abcam, Cambridge, England).

    2.15 In Vitro Assessment of the Cancer Cell-Killing Activity of Nanoparticle-Stimulated T Cells

    The ability of nanoparticle-treated T cells to kill B16F10 melanoma cells was measured by fluorescence dye staining and live, real-time video monitoring. T cells from splenocytes were exposed to tumor-associated antigens and treated with various nanoparticle preparations. To better mimic the in vivo tumor microenvironment, we isolated splenocytes from spleens of adjuvant-treated B16F10 tumor-bearing mice. In brief, C57BL/6 mice were inoculated subcutaneously with B16F10 cells (5 × 105cells). Seven days after tumor inoculation, doxorubicin (DOX; Sigma-Aldrich), used as an immunogenic cell death inducer [27], was injected intratumorally at a dose of 50 μg/mouse together with monophosphoryl lipid A (MPL; InvivoGen, San Diego, CA, USA), used as an adjuvant [28], at a dose of 20 μg/mouse [29]. After 2 days, mice were sacrificed and splenocytes were isolated from the spleen and antigenically stimulated with B16F10 lysates, prepared by repeatedly freezing and thawing (5 cycles) B16F10 cells (2 × 105cells mL-1). Splenocytes were incubated with the resulting tumor lysates for 48 h, after which collected T cells were treated with various nanoparticle preparations with or without 20 μM fenofibrate for 48 h, and then further treated with low-glucose medium containing 40 μM palmitate-BSA for 24 h.

    The cancer cell-killing activity of T cells was evaluated by first seeding B16F10 cells, pre-stained with CellTracker Green CMFDA Dye (Thermo-Fisher Scientific), onto a 24-well plate (1 × 104cells/well) and co-culturing them with B16F10 tumor lysate-stimulated T cells (1 × 106cells/well). After 24 h, cancer cells were stained with PI, and the population of dead (CMFDA+/PI+) cancer cells was analyzed by flow cytometry. In some experiments, the anticancer effects of T cells were evaluated by staining T cells with FITC-conjugated anti-mouse CD3 antibody or APCconjugated anti-mouse CD3 antibody (BioLegend; catalog #100235, clone 17A2, lot #B256435). Then, the cells were fixed and permeabilized using a transcription factor buffer set (BioLegend) and incubated with Alexa Fluor 647-conjugated anti-mouse granzyme B antibody (BioLegend; catalog #515406, clone GB11, lot #B233111) or PE-conjugated anti-mouse IFN-γ antibody (BioLegend; catalog #505808, clone XMG1.2, lot #B265789). After 1 h, the percentages of CD3+Granzyme B+or CD3+IFN-γ+cells were analyzed by flow cytometry. For real-time monitoring of stimulated T cell-mediated cancer cell lysis, T cells pre-stained with CellTracker Green CMFDA dye were seeded onto a 24-well plate and cocultured with B16F10 cells stained with Cell-Tracker Red CMTPX dye (Thermo-Fisher Scientific) at a T cell:cancer cell ratio of 100:1. Cancer cell lysis was recorded in real time over 45 h using an Operetta High-Content Imaging System (PerkinElmer, Waltham, MA, USA).

    2.16 In Vitro Study of FoxP3 Expression

    The expression levels of FoxP3 in T cells after treatment with various nanoparticles were evaluated by flow cytometry. T cells were seeded onto 24-well plates (1 × 106cells/well) and treated with various nanoparticles containing 20 μM fenofibrate for 48 h. Cells were harvested, washed with PBS and stained with FITC-conjugated anti-mouse CD3 antibody, PE/Cy5-conjugated anti-mouse CD25 antibody (Biolegend; catalog #102010, lot #B277468) and PEconjugated anti-mouse CD4 antibody (Biolegend; catalog #116006, lot #B255181) for 1 h. Cells were fixed and permeabilized using a transcription factor buffer (BioLegend) and incubated with APC-conjugated anti-mouse FoxP3 antibody (Invitrogen; catalog #17-5773-82, lot #1984797) for 1 h.

    2.17 In Vivo T Cell Targeting of Nanoparticles

    In vivo T cell targeting of nanoparticles was evaluated using molecular imaging and flow cytometry. Six-week-old mice were subcutaneously inoculated in the right flank with 5 × 105B16F10 cells. After 7 days, mice were injected intratumorally with various FITC-labeled nanoparticle preparations. For molecular imaging, the fluorescence intensity of tumor tissue was recorded at various time points using an IVIS Spectrum in Vivo Imaging System (PerkinElmer). For flow cytometry, tumors were extracted at 24 h immediately after injection of FITC-labeled nanoparticles. T cells in extracted tumors were analyzed by incubation with APCconjugated anti-mouse CD3 antibody and the percentage of CD3+FITC+cells was determined by flow cytometry.

    The distribution of nanoparticles to T cells was visualized by first extracting the tumor and fixing it by incubating with 4% formaldehyde for 4 h at RT. The tissue was then embedded in OCT cryostat sectioning medium, frozen at -80 °C and sectioned at 10 μm using a Leica CM 3050 S microtome (Leica). The tumor sections were washed three times with PBS and blocked with 1% BSA in PBS for 30 min. After blocking, the sections were incubated with APC-conjugated anti-CD3 antibody (BioLegend; catalog #100235, lot #B290370) for 12 h at 4 °C. After staining with DAPI, tissue fluorescence was assessed under a confocal laser-scanning microscope (LSM 5 Exciter; Carl Zeiss).

    2.18 In Vivo PPARα Expression Measurement

    T cell lipid metabolism in vivo was evaluated by measuring PPARα expression. B16F10 cells (5 × 105cells) were subcutaneously inoculated into the right flank of 5-wk-old C57BL/6 mice. After 7 days, DOX (50 μg/mouse) and MPL (20 μg/mouse) were injected intratumorally. On days 10 and 12 after B16F10 cell inoculation, various nanoparticle preparations (18 μg fenofibrate/mouse) were administered intratumorally. On day 14, mice were sacrificed and extracted tumors were stained with FITC-conjugated anti-mouse CD3 antibody and Alexa Fluor 647-conjugated anti-mouse PPARα antibody (Santa Cruz Biotechnology; catalog #sc-398394, lot #H1017) for 1 h, followed by flow cytometry. For immunofluorescence staining, tumors were extracted and fixed with 4% formaldehyde for 4 h at RT, after which the tissue was embedded in OCT and cryosectioned at a thickness of 10 μm with a Leica CM 3050 S microtome (Leica). After permeabilizing tissue with 0.3% Triton X-100 (Sigma-Aldrich) in PBS for 10 min and blocking with 0.025% Triton X-100 and 1% BSA in PBS for 1 h, the sections were incubated with FITC-conjugated anti-mouse CD3 antibody and Alexa Fluor 647-conjugated anti-mouse PPARα antibody (Santa Cruz Biotechnology). Tissues were then counterstained with DAPI and observed under a confocal laser-scanning microscope (LSM 5 Exciter; Carl Zeiss).

    2.19 In Vivo Lipid Uptake and Metabolite Imaging in T Cells

    Lipid uptake and metabolism in T cells were assessed by flow cytometry and matrix-assisted laser desorption ionization (MALDI) imaging mass spectrometry, respectively. Briefly, mice were injected intratumorally with 25 μg kg-1BODIPY C16on the day after the last injection of nanoparticles. After 4 h, tumors were extracted and T cells were stained with APC-conjugated anti-mouse CD3 antibody for 1 h and the percentage of CD3+BODIPY+T cells was analyzed by flow cytometry. For lipid metabolite analysis, F/ANs and aCD3/F/ANs were administered intratumorally on days 10 and 12. On day 14, tumors were extracted and embedded in 2% carboxymethyl cellulose (Sigma-Aldrich) and cryosectioned at 10 μm with a Leica CM 3050 S microtome (Leica). Frozen tissue sections were mounted onto indium-tin-oxide—coated glass slides (Bruker, Billerica, MA, USA) and then were sprayed with 10 mg/ml solution of a α-cyano-4-hydroxycinnamic acid (Bruker) in 70% acetonitrile with 0.1% trifluoroacetic acid. The samples were scanned over the relevant molecular weights, and the distribution of representative metabolites was determined using a rapifleX system (Bruker).

    2.20 In Vivo Assessment of Fatty Acid Oxidation-Associated Gene Expression

    In vivo expression levels of fatty acid oxidation-associated genes in CD3-positive T cells were measured RT-PCR and western blot. Briefly, tumors were extracted and digested by 1 mg mL-1collagenase (Sigma-Aldrich). Single cells were stained with APC conjugated anti-mouse CD3 antibody and CD3-positive cells were collected using BD FACSAria? III sorter (BD Biosciences, San Jose, CA, USA). For RTPCR, total RNA was isolated from CD3-expressing T cells using the TRIzol reagent (Thermo-Fisher Scientific). cDNA was synthesized from mRNA using an AccuPower RT Pre-Mix. Quantitative real-time RT-PCR was performed using a LightCycler FastStart DNA Master SYBR Green I system. For western blot, CD3-expressing T cells were lysated with RIPA buffer containing protease inhibitor. The amounts of protein were quantified by BCA assay. Primary antibodies for detecting following proteins were uses: anti-mouse CPT1B (Proteintech), anti-mouse LCAD (Proteintech), antimouse MCAD (Proteintech) and anti-mouse β-actin (Cell signaling). Horseradish peroxidase-linked anti-rabbit IgG (Cell signaling) was used as secondary antibody. Amersham ECL Prime Western Blotting detection reagent was used for signal detection.

    2.21 In Vivo Antitumor Efficacy

    The in vivo antitumor activity of various nanoparticle preparations was evaluated by monitoring B16F10 tumor growth. B16F10 cells (5 × 105cells) were subcutaneously inoculated into the right flank of 5-week-old C57BL/6 mice. After 7 d, DOX (50 μg/mouse) and MPL (20 μg/mouse) were injected intratumorally, and on days 10 and 12, various nanoparticle preparations containing fenofibrate (18 μg/mouse) were administered intratumorally. Tumor size was measured in two dimensions every 2 days using a slide caliper, and tumor volume was calculated asa×b×b× 0.5, whereaandbare the lengths of the largest and smallest dimensions [16].

    2.22 Detection of Tumor-Infiltrating Lymphocytes and Cytokines

    Tumor infiltrating lymphocytes (TILs) and cytokines in tumor tissues were measured by flow cytometry and immunofluorescence staining. For flow cytometry, extracted tumors were digested by incubating with 1 mg mL-1collagenase (Sigma-Aldrich) in RPMI-1640 medium and the resulting cell suspensions were stained with a mixture of FITC-conjugated anti-mouse CD3 antibody and APCconjugated anti-mouse CD8a antibody (BioLegend; catalog #100712, clone 53—6.7, lot #B266721) for 1 h. TIL function was assessed by staining cell suspensions with FITC-conjugated anti-mouse CD3 antibody, Alexa Fluor 647-conjugated anti-human/mouse granzyme B antibody (BioLegend; catalog #515406, clone GB11, lot #B233111), and PE-conjugated anti-mouse IFN-γ antibody (BioLegend; catalog #505808, clone XMG1.2, lot #B265789) for 1 h.

    For immunofluorescence staining, tumors were first extracted and fixed with 4% formaldehyde for 4 h at RT. The tissue was then embedded in OCT and cryosectioned at a thickness of 10 μm using a Leica CM 3050 S microtome (Leica). After tissue permeabilization, sections were incubated with PerCP/cyanine 5.5-conjugated anti-CD8 antibody (Bio-Legend; catalog #100734; lot #B277115), PE-conjugated anti-IFN-γ antibody, and Alexa Fluor 647-conjugated anti-human/mouse granzyme B antibody for 12 h at 4 °C. The tissue was then washed three times with PBS, followed by staining with DAPI. Tissue fluorescence was observed using a confocal laser-scanning microscope (LSM 5 Exciter; Carl Zeiss).

    2.23 In Vivo Toxicity Study

    Five-week-old C57BL/6 mice were subcutaneously injected twice with various nanoparticles. Two days after first injections, whole blood and serum samples were collected for analysis of hematological parameters regarding to white blood cell (WBC), red blood cell (RBC), hemoglobin (Hb), hematocrit (HCT), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), neutrophil, lymphocyte, monocyte, eosinophil, alanine aminotransferase (ALT), aspartate transaminase (AST), blood urea nitrogen (BUN) and creatinine. Organs (liver, lung, heart, spleen and kidney) were collected for hematoxylin and eosin staining.

    2.24 Statistics

    Two-side analysis of variance (ANOVA) with post hoc Student—Newman—Keuls test was used for statistical analyses. Experimental data were analyzed with SigmaStat software (version 12.0, Systat Software). AP-value less than 0.05 was considered statistically significant.

    3 Results and Discussion

    3.1 Characterization of aCD3/F/ANs

    aCD3/F/ANs were characterized based on the physicochemical features of morphology, size, and surface charge. The structures of the various nanoparticle preparations are illustrated in Fig. 2a. Hydrophobic fenofibrate was encapsulated in selfassembled AP nanoparticles, and the surfaces of F/ANs were chemically modified with an anti-CD3 antibody, resulting in aCD3/F/ANs. TEM revealed that aCD3/F/AN particles were spherical in shape (Fig. 2b), and dynamic light scattering data showed that the sizes of aCD3/F/ANs did not significantly differ compared with those of F/ANs (Fig. 2c). The surface zeta potentials of all nanoparticles were negative regardless of antibody modification (Fig. 2d). EDS-TEM showed the presence of elemental sulfur in aCD3/F/ANs, reflecting the presence of the anti-CD3 antibody (Fig. 2e). The amount of fenofibrate per nanoparticle was not significantly different between F/ANs and aCD3/F/ANs (Fig. 2f). F/ANs and aCD3/F/ANs retained their stability in PBS for at least 7 days (Fig. 2g). The in vitro release of fenofibrate from aCD3/F/ANs was pH-dependent. At pH 7.4 and 6.8, less than 20% of fenofibrate was released from nanoparticles over 8 h. However, at pH 5.0, the release of fenofibrate from aCD3/F/ANs was greater than 60% at 8 h (Fig. 2h).

    3.2 Uptake of aCD3/F/ANs by T Cells

    The uptake of aCD3/F/ANs by T cells was monitored by confocal microscopy (Fig. 3a) and flow cytometry (Fig. 3b, c) using fluorescent dye-labeled nanoparticles. Confocal fluorescence microscopy revealed negligible uptake of F/fANs by T cells. Similarly, there was no notable uptake of a physical mixture of anti-CD3 antibody and fANs. In contrast, treatment with aCD3/F/fANs resulted in higher uptake of nanoparticles by T cells. Consistent with confocal microscopy images, flow cytometry showed that the fluorescence-positive T cell population was highest after treatment with aCD3/F/fANs (Fig. 3b), which resulted in a 3.8-fold higher fluorescence-positive T cell population compared with that observed in other treatment groups (Fig. 3c).

    3.3 Effect of aCD3/F/ANs on the Expression of Fatty Acid Metabolism-Related Genes and Lipid Uptake in T Cells

    Treatment of T cells with aCD3/F/ANs affected fatty acid oxidation-related gene expression levels and lipid uptake. The cellular mechanism underlying PPARα-mediated lipid metabolism enhancement is shown in Fig. 4a. To evaluate metabolic reprogramming quantitatively, the expression levels of PPARα in T cells were measured by flow cytometry. In the T cells treated with aCD3/F/ANs, the highest expression of PPARα was observed at protein level (Fig. 4b) and mRNA level (Fig. S4b). The PPARα-positive T cell population increased by more than 7.2-fold upon treatment with aCD3/F/ANs compared with the untreated group. In addition, the expression level of a fatty acid translocase CD36, which exists on cell membrane, was also evaluated by flow cytometry. The expression of CD36 was 2.2-fold higher in the aCD3/F/AN group compared with the F/AN group (Figs. 4c and S4e). Western blot data showed that aCD3/F/ANs significantly increased the protein expression levels of CPT1B, LCAD, and MCAD compared to untreated and other groups (Figs. 4d and S5). Consistently, mRNA level of CPT1B, LCAD and MCAD was increased by 4.4-fold, 2.5-fold and 2.8-fold, respectively, compared with untreated cells (Fig. 4g). Since one consequence of the observed changes in gene expression is an increased rate of lipid uptake, we measured lipid uptake by T cells using fluorescent dye-labeled lipid, BODIPY C16. Compared with untreated cells, T cells treated with ANs, aCD3/ANs, F/AN or with a mixture of anti-CD3 antibody and F/ANs (aCD3 + F/ANs) showed no significant change in lipid uptake by T cells (Fig. 4e). In contrast, treatment of T cells with aCD3/F/ANs increased lipid uptake 3.1-fold compared with untreated cells (Fig. 4f).

    Fig. 2 Characterization of nanoparticles. a Schematic illustration of ANs, aCD3/ANs, F/ANs and aCD3/F/ANs. b Morphology of aCD3/F/ANs, observed by TEM. Scale bar: 200 nm. c Mean particle size of different nanoparticles, determined using DLS. d Zeta potential of nanoparticles, measured by laser Doppler microelectrophoresis. e Characterization of aCD3/F/ANs with respect to the elements oxygen, chloride and sulfur, conducted by STEM-EDS. Scale bar: 200 nm. f Amount of fenofibrate encapsulated in nanoparticles, quantified by HPLC. g Particle sizes of F/ANs and aCD3/F/ANs in PBS, monitored for 7 days. h Release of fenofibrate from aCD3/F/ANs, quantified by HPLC under different pH conditions (***P < 0.001)

    Fig. 3 Uptake of nanoparticles by T cells. Mouse spleen-derived T cells were incubated with various fenofibrate-containing nanoparticle preparations. After 24 h, cellular uptake of nanoparticles was visualized by confocal microscopy a and quantified by flow cytometry b, c (***P < 0.001, n.s., not significant). Scale bar: 10 μm

    Fig. 4 Fatty acid metabolism-associated gene expression and lipid uptake in T cells. a The cellular mechanism underlying aCD3/F/AN-induced enhancement of lipid metabolism is illustrated. The left half of the schematic cell depicts the untreated condition, and the right half shows treatment with aCD3/F/ANs. aCD3/F/AN treatment is proposed to activate PPARα in T cells, leading to over-expression of fatty acid metabolism-associated proteins, including CD36 (fatty acid translocase), CPT1B, LCAD and MCAD. The increased fatty acid metabolism in mitochondria generates higher energy via the TCA cycle. b The corresponding levels of PPARα protein in T cells (PPARα+/CD3+), measured by flow cytometry. c The levels of CD36 protein in T cells (CD36+/CD3+), measured by flow cytometry. d Protein expression levels of CPT1B, LCAD and MCAD in T cells were measured by western blot. e, f T cells treated with different nanoparticle preparations were incubated with fluorescent lipid BODIPY C16, and the association of fluorescent lipid with T cells was determined by flow cytometry (e) and expressed as mean fluorescence intensity (f) (***P < 0.001). g mRNA expression levels of the fatty acid metabolism-associated genes, CPT1B, LCAD and MCAD, determined by RTPCR (***P < 0.001)

    3.4 T Cell Mitochondrial Activation by aCD3/F/ANs

    Mitochondrial functions in T cells, including fatty acid metabolism, were modulated by treatment with aCD3/F/ANs. To mimic the glucose-deficient tumor microenvironment, we incubated T cells in low-glucose medium. In low-glucose environment containing palmitate as a lipid source, untreated T cells or T cells treated with nanoparticles such as AN, aCD3/AN and F/AN showed poorlydefined mitochondrial cristae with shrunken morphologies compared to the mitochondrial of T cells in high-glucose condition (Figs. 5a and S6). In contrast, T cells treated with aCD3/F/ANs showed mitochondrial structures with clear cristae, similar to those observed in high glucose environment (Fig. 5a).

    In addition to altering the morphology of mitochondria, aCD3/F/ANs increased mitochondrial membrane potential, with fluorescent dye staining revealing the highest mitochondrial membrane potential in T cells treated with aCD3/F/ANs (Fig. 5b). Under low-glucose conditions, mitochondrial membrane potential did not differ among groups (Fig. S7a, b). However, treatment with aCD3/F/ANs in palmitate-supplemented low-glucose medium expanded the population of T cells with increased mitochondrial membrane potential by more than 6.3-fold compared with other treatment groups (Fig. 5c).

    aCD3/F/AN-mediated delivery of fenofibrate to T cells enhanced lipid metabolism and mitochondrial activity. However, the ECAR value, an indicator of glycolysis, showed little difference among groups, suggesting similar levels of glycolysis in all groups (Fig. 5d). In contrast to ECAR, basal OCR, an indicator of mitochondrial respiration, was significantly higher in the aCD3/F/AN-treatment group compared with other groups (Fig. 5e, f). In addition, spare respiratory capacity (SRC), which is related to the extra ATP capacity produced by mitochondrial metabolism during a sudden increase in energy demand (calculated by subtracting minimal respiration from maximal respiration), was highest in the aCD3/F/AN-treatment group, reaching a level eightfold higher than that in the F/AN group (Fig. 5g). Moreover, the aCD3/F/AN group exhibited the highest ratio of OCR to ECAR, with a value 2.2-fold higher than that of the F/AN-treated group (Fig. 5h). Consistent with the observed enhancement in lipid metabolism, aCD3/F/AN treatment significantly increased the production of β-hydroxybutyrate, a major lipid metabolite (Fig. 5i), increasing it by 2.2-fold upon palmitate supplementation compared with F/ANs. In contrast, β-hydroxybutyrate levels were not significantly changed by AN, F/AN, aCD3/AN or aCD3 + F/AN treatment in the presence or absence of supplemental palmitate (Fig. S8a).

    3.5 In Vitro Proliferation of Metabolically Reprogrammed T Cells

    Treatment with aCD3/F/ANs affected the survival and proliferation of T cells. In these experiments, T cells were treated with various nanoparticle formulations under glucose-deficient conditions. In some experiments, low glucose medium was supplemented with palmitate as a lipid source. Fluorescent dye-based live/dead assays revealed that, in such a glucose-deficient, but palmitate-replete, environment, the aCD3/F/AN-treatment group showed the highest fraction of live T cells (Fig. 6b) and a significantly higher annexin V—/PI—cell population compared with other treatment groups (Fig. 6c, d). In addition, upon palmitate supplementation, the proliferation of aCD3/F/AN-treated T cells was 5.4-fold higher than that in the untreated group (Fig. 6e).

    3.6 In Vitro Cancer Cell-Killing Activity of aCD3/F/AN-Treated T Cells

    The treatment with aCD3/F/ANs enhanced the cancer cellkilling activity of T cells. Upon co-incubation of T cells with B16F10 melanoma cells, the levels of granzyme B and IFN-γ in aCD3/F/AN-treated T cells were 2.3- and 3.0-fold higher compared with those in the F/AN-treated group, respectively (Fig. 7b—e). The cancer cell-killing activity of T cells treated with ANs, F/ANs, aCD3/AN or aCD3 + F/AN was not different from those of untreated T cells (Fig. 7f). However, the population of dead cancer cells following incubation with aCD3/F/AN-treated T cells was 15.6-fold higher than that following incubation with T cells treated with aCD3 + F/ANs (Figs. 7f and S9). Real time video recordings further showed that untreated T cells did not attack B16F10 cells (Supplementary Video S1), whereas aCD3/F/AN-treated T cells vigorously attacked B16F10 cells (Supplementary Video S2). Still images of untreated T cells and aCD3/F/AN-treated T cells captured at various time points are shown in Fig. 7g.

    Fig. 5 Mitochondrial morphology, membrane potential and fatty acid metabolism in T cells. T cells were treated with aCD3/F/ANs in lowglucose medium supplemented with palmitate as a lipid source. a TEM showing mitochondria of T cells in high-glucose medium, low-glucose medium untreated or treated with aCD3/F/AN. Scale bar: 1 μm (upper panels) and 500 nm (lower panels). b Mitochondrial membrane potential, assessed using MitoTracker Orange CMTMRos and visualized by confocal fluorescence microscopy. c Populations of T cells with increased mitochondrial membrane potentials, quantified by flow cytometry. d, e ECAR (d) and OCR (e), measured using a Seahorse XFp analyzer. f-h Basal OCR (f), SRC (g) and OCR/ECAR h values, obtained based on ECAR and OCR values (*P < 0.05, **P < 0.01). i β-Hydroxybutyrate secretion levels (***P < 0.001)

    Fig. 6 Enhanced T cell survival and proliferation induced by metabolic reprogramming. T cells were activated and treated with various nanoparticle preparations and incubated under glucose-limiting conditions, with or without a lipid source. a Illustration of the experimental scheme. b Live and dead T cells, visualized by fluorescent dye staining. Scale bar: 10 μm. c, d T cells were stained with annexin V and PI, and the annexin V—/PI—population was quantified for each group (***P < 0.001). e Proliferation of T cells, measured using WST-1 assays (***P < 0.001)

    3.7 In Vivo Distribution of aCD3/F/ANs to T Cells in Tumor Tissues

    The in vivo distribution of nanoparticles to T cells in tumor tissues was visualized by determining colocalization with T cells in fluorescence images. aCD3/F/fANs showed the highest retention in tumor tissues compared with F/fANs and the aCD3 + F/AN group (Fig. 8a). An intensity analysis showed that the distribution of nanoparticles to tumor tissues over 72 h post-dose was highest in the group treated with aCD3/F/fANs (Fig. 8b). At 72 h, ex vivo fluorescence imaging of extracted tumor tissues revealed that aCD3/F/fANs were retained to a higher extent than other nanoparticle preparations (Fig. S9). Uptake of nanoparticles by T cells in tumor tissues was tested by assessing colocalization of nanoparticles and the FITC+CD3+T cell population. The colocalization of nanoparticles to CD3+T cells was highest in the aCD3/F/fAN-treatment group, which exhibited 7.6-fold greater colocalization than the F/fAN group at 24 h (Fig. 8c, d). Tumor tissue staining showed higher colocalization of aCD3/F/fANs with CD3+T cells in tumor tissues (Fig. 8e).

    3.8 Reprogramming of In Vivo Fatty Acid Metabolism in aCD3/F/AN-Treated T Cells

    The intratumoral administration of aCD3/F/ANs modulated in vivo PPARα expression, lipid uptake and metabolism by T cells. The in vivo experimental scheme is illustrated in Fig. 9a. Flow cytometry showed that PPARα-positive (Fig. 9b) and BODIPY C16-positive (Fig. 9c). T cell populations were increased to a greater extent in the aCD3/F/AN-treatment group. Expression of PPARα was increased 4.1-fold and 2.6-fold in this group compared with F/AN- and aCD3 + F/AN-treatment groups, respectively (Fig. 9d). Uptake of BODIPY C16lipid was almost twofold higher in the aCD3/F/AN-treatment group than in other groups (Fig. 9e). Mice treated with aCD3/F/AN showed significantly increased protein expression and mRNA levels of CPT1B, LCAD and MCAD compared with untreated group (Fig. 9f, g). Immunostaining revealed distinct PPARα expression in CD3+T cells in tumor tissues, as demonstrated by colocalization of CD3 and PPARα staining (Fig. 9h, i). MALDI imaging revealed enhanced levels of the fatty acid oxidation metabolites, acetoacetate, β-hydroxybutyrate and palmitoylcarnitine, in T cells treated with aCD3/F/ANs (Fig. 9j).

    3.9 In Vivo Antitumor Efficacy of Metabolically Reprogrammed T Cells

    To assess the effects of aCD3/F/ANs on tumor growth and the survival of mice, we intratumorally injected B16F10 tumor-bearing mice with various nanoparticle preparations twice, once on day 10 after tumor inoculation and again on day 12 (Fig. 10a). aCD3/F/AN treatment exerted significantly higher tumor growth-inhibitory effects than treatment with other nanoparticle preparations (Fig. 10b, c). Notably, the survival rate of mice treated with aCD3/F/ANs was 100% up to day 60. In contrast, no mice survived beyond 44 days after tumor inoculation in any other treatment group (Fig. 10d).

    To test whether the observed antitumor efficacy was attributable to the enhanced function of metabolically reprogrammed T cells, we quantified tumor-infiltrating CD8+T cells (Fig. 11b). The CD8+T cell population in tumor tissues was significantly increased in mice treated with aCD3/F/ANs, which exhibited a CD8+T cell population in tumor tissues 14.8-times higher than that in F/ANtreated mice (Fig. 11b, e). In vivo treatment with aCD3/F/ANs affected expression levels of IFN-γ and granzyme B in T cells. Specifically, IFN-γ—expressing T cells accounted for 20.5% ± 4.1% of tumor T cells in the aCD3/F/AN-treated group—a more than fivefold increase compared with F/AN- and aCD3 + F/AN-treatment groups (Fig. 11c, f). Similar to the IFN-γ expression pattern, the highest percentage of granzyme B—expressing T cells was observed for the group treated with aCD3/F/ANs, which showed more than a 3.9-fold increase in levels compared with other treatment groups (Fig. 11d, g). An immunohistochemical analysis of tumor tissues showed no notable infiltration of CD8+T cells in tumor tissues in the untreated mice (Fig. 11h). However, considerable infiltration of CD8+T cells in tumor tissues and secretion of IFN-γ and granzyme B were observed in tumors treated with aCD3/F/ANs (Fig. 11i).

    Fig. 7 In vitro anticancer activity of aCD3/F/AN-treated T cells. T cells were treated with various nanoparticle preparations and co-incubated with B16F10 cells under glucose-limiting conditions in the presence of palmitate as a lipid source. a Illustration of the experimental scheme. b, c Flow cytometry data of T cells positive with granzyme B (b) and IFN-γ (c). d, e The populations of T cells positive with granzyme B (d) and IFN-γ (e) were quantified. (***P < 0.001). f Dead cancer cell population, quantified by flow cytometry (***P < 0.001). g Lysis of cancer cells by T cells, recorded in real time. Cancer cells were labeled with red fluorescent dye, whereas T cells were labeled with green fluorescent dye. Realtime video recordings of untreated T cells or T cells treated with aCD3/F/ANs are shown in Supplementary video S1 and S2, respectively

    Fig. 8 In vivo T cell-targeting ability of aCD3/F/ANs. T cell targeting ability was evaluated by intratumorally injecting mice (n = 3) with various nanoparticle preparations containing fenofibrate. a In vivo fluorescence at tumor sites, visualized at different time points. b Quantification of fluorescence in tumor sites at different time points (**P < 0.01, ***P < 0.001). c Uptake of nanoparticles in tumor-resident T cells, analyzed by flow cytometry. d CD3+FITC+ T cell population, quantified for each treatment group (***P < 0.001). e Colocalization of nanoparticles (green) with CD3+ T cells (red), visualized by confocal microscopy. Scale bars: 20 μm

    Fig. 9 In vivo PPARα expression and lipid uptake by T cells in tumor tissues. a B16F10 tumor-bearing mice were intratumorally injected with various nanoparticle preparations on days 10 and 12 after tumor inoculation. On day 13, BODIPY C16 was intratumorally injected, and on day 14, tumor tissues were extracted and analyzed. b—e PPARα expression level in T cells (b, d) and BODIPY C16-positive CD3 T cells (c, e), analyzed by flow cytometry (***P < 0.001). f Protein expression levels of CPT1B, LCAD and MCAD in tumor infiltrating T cells were determined by western blot. g mRNA expression levels of the fatty acid metabolism-associated genes CPT1B, LCAD and MCAD in tumor infiltrating T cells were determined by RT-PCR (***P < 0.001). h, i Confocal microscopic images of untreated (h) and aCD3/F/AN-treated tumor tissue (i) were immunostained with anti-CD3 (green) and anti-PPAR α (red) antibody and counterstained with DAPI. Scale bars: 100 μm. j Tumor tissue distribution of acetoacetate (m/z = 103.09), β-hydroxybutyrate (m/z = 105.10) and palmitoylcarnitine (m/z = 400.60), as visualized by MALDI imaging. Scale bar: 5 μm

    Fig. 10 Antitumor effects of aCD3/F/ANs in vivo. a B16F10 tumor-bearing mice were intratumorally injected with various nanoparticle preparations on days 10 and 12 after tumor inoculation. b, c Antitumor efficacy, determined by measuring tumor volume. d Survival rate in each mouse group, monitored for 60 days after tumor inoculation

    Here, we demonstrated that enhanced delivery of fenofibrate to T cells modulated the fatty acid metabolism of T cells and stimulated their cancer cell-killing activity. T cell-directed delivery of fenofibrate was achieved by modification of the surfaces of fenofibrate-loaded nanoparticles with an anti-CD3 antibody. Uptake of aCD3/F/ANs by T cells increased mitochondrial function and the expression of fatty acid metabolism-related genes, including PPARα. T cells metabolically reprogramed by aCD3/F/ANs efficiently killed B16F10 melanoma cells in vitro, and an in vivo study showed that aCD3/F/AN treatment prevented the growth of tumors and increased the production of various cytokines.

    In this study, we entrapped fenofibrate in ANs and modified the surfaces of F/ANs with anti-CD3e f(ab’)2 antibody fragments. The nanoparticle is based on the amphiphilic derivative of poly (γ-glutamic acid) which is natural biopolymer produced from Bacillus species [30]. Due to the biocompatibility and biodegradability, poly (γ-glutamic acid)-based biomaterials have been studied for delivery systems of various active substances. Poly (γ-glutamic acid) and gold nanocluster hybrid nanoparticles were reported for receptor-mediated cancer cell delivery and photothermal therapy [31]. Poly (γ-glutamic acid) coating of doxorubicin-loaded mesoporous silica nanoparticle was shown to increase the delivery to cancer cell and enhance the anticancer effect of doxorubicin [32]. Amphiphilic phenylalanine derivative of poly (γ-glutamic acid) was found to self-assemble polymeric micelles and entrap hydrophobic anticancer drugs in the hydrophobic phenylalanine core parts [22]. Moreover, the carboxylic groups at the surfaces of amphiphilic poly (γ-glutamic acid)-based nanoparticles enable the surface modification with other functional molecules such as targeting ligand chemicals and antibodies [33].

    Fig. 11 In vivo cytokine production by T cells in tumor tissues. a B16F10 tumor-bearing mice were injected with nanoparticle preparations on days 10 and 12 after tumor inoculation. On day 14, tumor tissues were extracted for analysis. b-d Infiltrating CD8+ T cells (b), IFN-γ—expressing T cells (c) and granzyme B—expressing T cells (d) among tumor tissue CD3+ T cells, determined by flow cytometry (***P < 0.001). Populations of CD3+/CD8+ cells (e), CD3+/ IFN-γ+ cells (f) and CD3+/granzyme+ cells (g) are shown. h, i In untreated (h), and aCD3/F/AN-treated mice (i), tumor tissues were extracted and immunostained with anti-CD8 (yellow), anti-IFN-γ (green) and anti-granzyme B (light purple) antibodies and counterstained with DAPI. Scale bar: 20 μm

    Here, fenofibrate was encapsulated inside of the AN matrix, which is thought to provide a hydrophobic core by virtue of the phenylalanine moieties of AP. The release of fenofibrate from aCD3/F/ANs at lower pH values might be attributable to protonation of carboxyl groups in AP. The CD3 receptor, which has been used as a marker of T cells [34], was chosen as a target because it is overexpressed on T cells and has been reported to induce receptor-mediated endocytosis upon binding of nanoparticles [33]. Indeed, we observed enhanced uptake of aCD3/F/ANs by T cells compared with plain F/ANs both in vitro (Fig. 3) and in vivo in B16F10 tumor tissues (Fig. 8e). The comparable T cell uptake of aCD3/ANs (Fig. 3) supports the major role of CD3 antibody fragments in T cell delivery.

    The CD3 antibody-mediated delivery enabled aCD3/F/ANs to show high selectivity to T cells without side effect to other cells. Our data support that the expression levels of CD3 were notably higher in T cells compared to other cells (Fig. S1). In line with the CD3 expression levels, the uptake of aCD3/F/ANs was significantly higher in T cells compared to other cells such as BMDC, BMDM, MLg, MRC-5, and 293 T (Fig. S2). Although the cellular uptake patterns were affected by the expression levels of CD3, the viability of cells were not affected by the types of cells, and nanoparticles. In all cells tested, the viability was retained after treatment with various nanoparticles (Fig. S3).

    Consistently, our in vitro and in vivo toxicity study demonstrated that aCD3/F/AN did not induce any cytotoxicity (Fig. S3) or systemic side effects (Fig. S12). In vivo safety study revealed that the repeated injection of mice with aCD3/F/ANs did not alter histology (Fig. S12a) or organ functions, showing similar levels of ALT, AST, BUN and creatinine compared to untreated group (Fig. S12b). Moreover, the levels of ALT, AST, BUN in the group treated with aCD3/F/ANs did not significantly differ from those of untreated group.

    CD3 receptor-mediated enhanced delivery of fenofibrate to T cells was shown to induce the expression of fatty acid uptake- and metabolism-related genes (Fig. 4). We found that uptake of fluorescent lipid by T cells was increased only in aCD3/F/AN-treated T cells, and not T cell treated with other nanoparticle preparations (Fig. 4f, g). The higher uptake of fluorescent lipids by aCD3/F/AN-treated T cells may be attributable to upregulation of fatty acid transport, consistent with a previous report that PPARα agonists induce up-regulation of the fatty acid transporter, CD36 [35]. Indeed, we observed that expression of CD36 was highest in T cells treated with aCD3/F/ANs (Fig. 4c). CD36, known as fatty acid translocase, functions in mediating the entry of extracellular fatty acids into the cytosol of cells [36].

    Fatty acids entering T cells via CD36 can be transported to mitochondria, where they feed into the TCA cycle. We observed that treatment with aCD3/F/ANs increased the expression of CPT1B, LCAD, and MCAD (Fig. 4d, e). CPT1B is known to increase the transport of fatty acids from the cytosol to mitochondria [37], whereas LCAD and MCAD are involved in the β-oxidation of fatty acids [38, 39]. The increased expression of fatty acid oxidationrelated genes is attributable to the ability of the pharmacological agent fenofibrate to activate PPARα [40]. PPARα, the molecular target of fenofibrate, is a key transcriptional regulator of fatty acid oxidation-related genes. In association with enhanced expression of PPARα, we observed increased expression of the downstream fatty acid oxidation-related genes CPT1B, LCAD and MCAD. Consistent with this, it has been reported that expression of CPT1B, LCAD and MCAD is induced by activation of the transcription factor, PPARα [25].

    Our observations support the interpretation that uptake of aCD3/F/ANs by T cells activates fatty acid metabolism, but not glycolysis (Fig. 5). The significantly higher OCR and ECAR ratio in aCD3/F/AN-treated T cells further supports the conclusion that fenofibrate affected fatty acid metabolism. T cells were metabolically reprogrammed to take up and use fatty acids as an energy source. In the presence of a fatty acid energy source, the reprogrammed T cells maintained a higher metabolic state and enhanced mitochondrial function, as evidenced by the levels of lipid metabolites in aCD3/F/AN-treated T cells. Because our data showed that treatment with aCD3/ANs alone did not affect fatty acid metabolism, it is unlikely that fatty acid metabolism is affected by nanoparticles per se; instead enhanced fatty acid metabolism is attributable to activation of PPARα by fenofibrate. Consistent with this, it has been reported that fenofibrate activates PPARα in various cell types, including endothelial cells [41], cardiomyocytes [42], and adipocytes [43].

    The enhanced mitochondrial functions of aCD3/F/ANtreated T cells may be attributable to the prolonged survival, proliferation and effector functions of T cells (Figs. 6 and 7). T cells are known to undergo metabolic stress and exhibit mitochondrial dysfunction in glucose-deficient tumor microenvironments [44]. Our TEM imaging revealed a shrunken mitochondrial morphology and decreased mitochondrial membrane potentials in glucose-deprived T cells (Fig. 5). Mitochondrial membrane potential is known to play a crucial role in ATP production and maintenance of cellular functions [45]. Treatment with aCD3/F/ANs restored clear cristae structures and membrane potentials of mitochondria. Notably, treatment with aCD3/F/ANs enhanced the cancer cell-killing effector function of T cells, likely owing to the reprogramming of T cells to use fatty acids as an alternative energy source.

    Fatty acid metabolism via the TCA cycle, which can provide greater energy to T cells, may lead to the production of various cytokines, as underscored by several reports on the relationship between robust mitochondrial function and energy production in T cells on the one hand and cytokine secretion on the other. Consistent with this, we found that metabolic reprogramming of T cells by aCD3/F/ANs resulted in increased secretion of the cytokine, granzyme B (Fig. 7). It was previously reported that fenofibrate induces mitochondrial fatty acid oxidation-mediated augmentation of the effector function of T cells by enhancing granzyme B and IFN-γ secretion [21]. Other studies have also reported that mitochondrial metabolism is essential for the ability of T cells to adapt by rapidly modifying their energy requirements. It has been reported that memory CD8+T cells maintain a higher mitochondrial metabolic rate through fatty acid oxidation and actively produce the cytokines, IFN-γ and IL-2 [46]; their mitochondrial function and secretion of IL-2 and TNF-α are also enhanced by acute infection [47]. Our observations are in agreement with previous findings that mitochondrial function plays a crucial role in the production of cancer-killing cytokines by T cells.

    Although we targeted CD3, which is expressed in various types of T cells, our focus was mainly on the effect of metabolic manipulation on effector CD8+T cells. Mitochondrial energy production is known to be critical for the ability of CD8+T cells to exert their cytotoxic function. In the case of regulatory T cells, metabolic adaptations allow these cells to maintain their inhibitory immune functions with the help of FoxP3. Several studies have reported that FoxP3, acting as a master transcriptional regulator, reduces the dependence of regulatory T cells on glycolysis to favor the mitochondrial oxidation pathway, providing these cells with a metabolic advantage over CD8+T cells in low-glucose environments [48, 49]. It is unlikely that the improved effector function of T cells was dependent on the alterations of FoxP3 expression. In this study, we observed that aCD3/F/AN did not significantly affect the expression of FoxP3 in T cells (Fig. S10).

    The metabolic reprogramming of tumor-infiltrating T cells, as revealed by their elevated expression of PPARα in aCD3/F/AN-treated tumor tissues (Fig. 9), contributes to the anticancer efficacy of aCD3/F/ANs. An additional contributing factor is the enhanced in vivo delivery of aCD3/F/ANs to T cells in tumor tissues, which exceeded that of all other nanoparticle preparations (Fig. 8). In this study, to enhance infiltration of T cells into tumor tissues, we pretreated mice with DOX, which is reported to act as an immunogenic cell inducer [27], and MPL, used as an immunoadjuvant [28]. The enhanced infiltration and activation of T cells by aCD3/F/AN-induced metabolic reprogramming, in turn, enhanced the killing of tumor cells. This is supported by the production of the cytokines, IFN-γ and granzyme B (Fig. 11), the latter of which has been shown to be a marker of activated cytotoxic T cells [50].

    In this study, we achieved the selective activation of PPARα by delivering fenofibrate only to T cells using an aCD3 antibody fragment. The selective delivery of fenofibrate can increase the amount of fenofibrate available to T cells and reduce the nonspecific distribution of fenofibrate to other tissues of the body. The importance of selective T cell targeting is supported by our demonstration that the physical combination of aCD3/ANs + F/ANs produced no meaningful alterations in metabolism in virtually all experimental settings. Importantly, the lack of significant anticancer effect of aCD3/ANs + F/ANs (Figs. 7 and 10) and the observation that aCD3/F/AN treatment completely abrogated tumor growth in B16F10 tumor-bearing mice (Fig. 10) support the importance of T cell targeted delivery of nanoparticles.

    Although we targeted tumor-infiltrating T cells by aCD3/F/AN in this study, the concept of lipid metabolic reprogramming can be broadly applied to adoptive T cell transfer. Currently, the anticancer effects of chimeric antigen receptor-engineered T cells against solid tumors are limited, partly because of their diminished viability in the hypoglycemic tumor microenvironment [51]. For adoptive T cell transfer, ex vivo pretreatment of T cells with aCD3/F/ANs might be used to fortify the survival and effector functions of these cells in the tumor microenvironment.

    4 Conclusions

    In conclusion, we have provided evidence that metabolic reprogramming of T cells can be used as a new mode of anticancer immunometabolic therapy. The enhanced T cell delivery achieved using CD3/F/ANs was shown to activate fatty acid oxidation metabolic pathways and restore mitochondrial functions of T cells in a glucose-deficient environment. Treatment with aCD3/F/ANs also increased effector functions of T cells against tumor cells. We used T cells for metabolic reprogramming in the current study, but the concept of metabolic reprogramming as a strategy for activating anticancer effector functions can be broadly applied to the design of other immunometabolic therapies against solid tumors.

    AcknowledgementsThis research was supported by grants from the Ministry of Science and ICT, Republic of Korea (NRF-2018R1A2A1A05019203; NRF-2018R1A5A2024425), and the Korean Health Technology R&D Project (No. HI15C2842; HI18C2177; HI19C0664), Ministry of Health & Welfare, Republic of Korea.

    Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creat iveco mmons.org/licen ses/by/4.0/.

    Electronic supplementary materialThe online version of this article (https://doi.org/10.1007/s4082 0-020-00555-6) contains supplementary material, which is available to authorized users.

    亚洲av免费高清在线观看| 国产综合懂色| 97人妻精品一区二区三区麻豆| 免费观看精品视频网站| 嫩草影院入口| 精华霜和精华液先用哪个| netflix在线观看网站| 无人区码免费观看不卡| 亚洲无线在线观看| 男人舔奶头视频| 在线播放无遮挡| xxxwww97欧美| 日韩强制内射视频| 91午夜精品亚洲一区二区三区 | 老熟妇乱子伦视频在线观看| 精品无人区乱码1区二区| 日韩强制内射视频| 最新中文字幕久久久久| 欧美绝顶高潮抽搐喷水| 国产69精品久久久久777片| 免费观看人在逋| 亚洲精品日韩av片在线观看| 精品人妻偷拍中文字幕| 九色国产91popny在线| 午夜福利视频1000在线观看| 五月玫瑰六月丁香| 国产爱豆传媒在线观看| 国产亚洲精品综合一区在线观看| 在线免费十八禁| 99九九线精品视频在线观看视频| 亚洲精品日韩av片在线观看| 色综合色国产| 亚洲国产精品久久男人天堂| 18禁裸乳无遮挡免费网站照片| 99热只有精品国产| 日本黄大片高清| 亚洲成av人片在线播放无| 成年女人毛片免费观看观看9| 免费搜索国产男女视频| 久久精品久久久久久噜噜老黄 | 国产又黄又爽又无遮挡在线| 亚洲欧美日韩高清专用| 亚洲性夜色夜夜综合| 国产 一区精品| 在线观看66精品国产| 免费人成在线观看视频色| 亚洲成a人片在线一区二区| а√天堂www在线а√下载| 国产蜜桃级精品一区二区三区| 国产精品乱码一区二三区的特点| 国产精品久久久久久久久免| 国内毛片毛片毛片毛片毛片| 一a级毛片在线观看| 夜夜看夜夜爽夜夜摸| 午夜视频国产福利| 特大巨黑吊av在线直播| 欧美成人一区二区免费高清观看| 亚洲av免费在线观看| 欧美+亚洲+日韩+国产| 中文资源天堂在线| 国产成人aa在线观看| 在线免费观看的www视频| 看片在线看免费视频| 一级av片app| 亚洲四区av| av在线天堂中文字幕| 热99在线观看视频| av.在线天堂| 成人欧美大片| 91麻豆av在线| 春色校园在线视频观看| 久久久精品欧美日韩精品| 久久久成人免费电影| 91午夜精品亚洲一区二区三区 | 在线观看一区二区三区| 麻豆成人av在线观看| 小蜜桃在线观看免费完整版高清| 99热这里只有精品一区| 波野结衣二区三区在线| 精品午夜福利在线看| 亚洲av免费高清在线观看| 天天躁日日操中文字幕| 一区二区三区免费毛片| 久久久色成人| 亚洲精品乱码久久久v下载方式| 精品99又大又爽又粗少妇毛片 | 一区二区三区高清视频在线| 午夜福利在线观看免费完整高清在 | 日韩欧美一区二区三区在线观看| 老师上课跳d突然被开到最大视频| 国产精华一区二区三区| 极品教师在线免费播放| 91麻豆精品激情在线观看国产| 人人妻,人人澡人人爽秒播| 日韩中文字幕欧美一区二区| 欧美日韩国产亚洲二区| 精品久久久久久久久久免费视频| 成年免费大片在线观看| 国产亚洲av嫩草精品影院| 制服丝袜大香蕉在线| 精品午夜福利在线看| 男女下面进入的视频免费午夜| 神马国产精品三级电影在线观看| 网址你懂的国产日韩在线| 午夜日韩欧美国产| av在线老鸭窝| 亚洲人成网站在线播| 精品无人区乱码1区二区| 给我免费播放毛片高清在线观看| 亚洲av日韩精品久久久久久密| 国产精品久久久久久精品电影| www日本黄色视频网| 精品人妻偷拍中文字幕| 国产黄片美女视频| 亚洲成av人片在线播放无| 日韩大尺度精品在线看网址| 内地一区二区视频在线| 久久99热6这里只有精品| 亚洲四区av| 18禁裸乳无遮挡免费网站照片| 免费人成视频x8x8入口观看| 国产精品日韩av在线免费观看| 国产精品久久久久久精品电影| 亚洲精品日韩av片在线观看| 成人国产一区最新在线观看| 亚洲国产高清在线一区二区三| 伦理电影大哥的女人| 搡老熟女国产l中国老女人| 色综合婷婷激情| 精品久久久久久久人妻蜜臀av| 国产欧美日韩精品一区二区| 免费人成在线观看视频色| 欧美一级a爱片免费观看看| 联通29元200g的流量卡| 免费观看精品视频网站| 淫妇啪啪啪对白视频| 成年人黄色毛片网站| 99九九线精品视频在线观看视频| 美女高潮喷水抽搐中文字幕| av国产免费在线观看| 老熟妇仑乱视频hdxx| 欧美日韩综合久久久久久 | 久久精品国产亚洲av涩爱 | 日韩欧美三级三区| 91av网一区二区| 91午夜精品亚洲一区二区三区 | 久久6这里有精品| 黄色视频,在线免费观看| 国产一区二区在线av高清观看| 高清日韩中文字幕在线| 久久精品久久久久久噜噜老黄 | 亚洲av中文av极速乱 | 欧美黑人巨大hd| 最近视频中文字幕2019在线8| 国产精品一区二区三区四区久久| 成人国产麻豆网| 成人三级黄色视频| 人人妻人人澡欧美一区二区| 久久久久久九九精品二区国产| 熟女电影av网| 午夜福利18| 亚洲精品一卡2卡三卡4卡5卡| 天天一区二区日本电影三级| 18+在线观看网站| 国语自产精品视频在线第100页| 最好的美女福利视频网| 综合色av麻豆| 51国产日韩欧美| 午夜激情福利司机影院| 久久人妻av系列| 欧美最黄视频在线播放免费| 桃色一区二区三区在线观看| 久99久视频精品免费| 国内精品宾馆在线| 最近在线观看免费完整版| 午夜福利视频1000在线观看| 免费搜索国产男女视频| 色哟哟·www| 国产精品一及| 国产 一区精品| 亚洲乱码一区二区免费版| 亚洲 国产 在线| 国内精品美女久久久久久| 波野结衣二区三区在线| 中文资源天堂在线| 欧美高清成人免费视频www| 可以在线观看毛片的网站| 美女被艹到高潮喷水动态| 99热精品在线国产| 日日夜夜操网爽| 久久国产精品人妻蜜桃| 真实男女啪啪啪动态图| 午夜福利成人在线免费观看| 啦啦啦啦在线视频资源| 国产真实乱freesex| 最近在线观看免费完整版| 国产精品一区www在线观看 | 男女那种视频在线观看| 老司机福利观看| 午夜福利成人在线免费观看| 老司机福利观看| 亚洲avbb在线观看| 免费看av在线观看网站| 国产精品嫩草影院av在线观看 | 国内久久婷婷六月综合欲色啪| 久久久久性生活片| 欧美区成人在线视频| 欧美激情久久久久久爽电影| 99视频精品全部免费 在线| 亚洲专区中文字幕在线| 日本成人三级电影网站| 97热精品久久久久久| 可以在线观看的亚洲视频| 日韩 亚洲 欧美在线| aaaaa片日本免费| 蜜桃亚洲精品一区二区三区| 亚洲不卡免费看| 天堂影院成人在线观看| 国产单亲对白刺激| 久99久视频精品免费| 美女 人体艺术 gogo| bbb黄色大片| 两人在一起打扑克的视频| 亚洲精品456在线播放app | 亚洲av中文字字幕乱码综合| 亚洲在线自拍视频| 99热这里只有是精品50| 日韩一区二区视频免费看| 在线观看舔阴道视频| 国产成人一区二区在线| 亚洲中文日韩欧美视频| 天堂av国产一区二区熟女人妻| 欧美潮喷喷水| 国产在线男女| 色综合色国产| 变态另类成人亚洲欧美熟女| 国产黄片美女视频| 亚洲经典国产精华液单| 亚洲人成网站在线播放欧美日韩| 国产一区二区三区视频了| 91久久精品电影网| 我的老师免费观看完整版| 国产一级毛片七仙女欲春2| 国产亚洲精品久久久久久毛片| 亚洲电影在线观看av| 久久精品91蜜桃| 一进一出抽搐gif免费好疼| 搡老岳熟女国产| 国产高清激情床上av| 精品国产三级普通话版| 国产精品免费一区二区三区在线| 88av欧美| 噜噜噜噜噜久久久久久91| 久久6这里有精品| 成人午夜高清在线视频| 女人十人毛片免费观看3o分钟| 最近中文字幕高清免费大全6 | 午夜久久久久精精品| 一个人看的www免费观看视频| 日本 av在线| 最近最新免费中文字幕在线| 午夜久久久久精精品| 国产极品精品免费视频能看的| 精品午夜福利在线看| 18禁黄网站禁片午夜丰满| 在线播放无遮挡| 在线观看免费视频日本深夜| 久久精品人妻少妇| 久久久久久伊人网av| 国产亚洲91精品色在线| 久久中文看片网| 久久久久久国产a免费观看| 日韩欧美免费精品| 男人的好看免费观看在线视频| 一进一出抽搐动态| 久久精品国产亚洲网站| 欧美日韩亚洲国产一区二区在线观看| 一本精品99久久精品77| 欧美潮喷喷水| 亚洲av五月六月丁香网| av福利片在线观看| 一区二区三区高清视频在线| 2021天堂中文幕一二区在线观| 日日撸夜夜添| 九九热线精品视视频播放| 噜噜噜噜噜久久久久久91| 久久亚洲真实| 简卡轻食公司| 国产精品久久久久久久久免| 国产aⅴ精品一区二区三区波| 淫妇啪啪啪对白视频| 色综合婷婷激情| 精品福利观看| 成人毛片a级毛片在线播放| 美女免费视频网站| 一进一出好大好爽视频| 国产亚洲91精品色在线| 超碰av人人做人人爽久久| 在现免费观看毛片| 干丝袜人妻中文字幕| 亚洲一区高清亚洲精品| 亚洲国产精品久久男人天堂| 久久久久久久久中文| 亚洲中文字幕日韩| 久久人人精品亚洲av| 亚洲自偷自拍三级| 国产精品女同一区二区软件 | 日本熟妇午夜| 免费观看在线日韩| 久久欧美精品欧美久久欧美| 国内揄拍国产精品人妻在线| 国内揄拍国产精品人妻在线| 亚州av有码| 嫩草影院精品99| 丝袜美腿在线中文| 一本一本综合久久| 人妻久久中文字幕网| 日日摸夜夜添夜夜添小说| 亚洲专区国产一区二区| 国产一区二区三区视频了| avwww免费| av在线天堂中文字幕| 在现免费观看毛片| 久久99热6这里只有精品| 亚洲图色成人| 伊人久久精品亚洲午夜| 国产乱人视频| 亚洲国产欧美人成| 日韩亚洲欧美综合| 尤物成人国产欧美一区二区三区| 日韩精品中文字幕看吧| 久久欧美精品欧美久久欧美| 少妇被粗大猛烈的视频| 欧美黑人欧美精品刺激| 我要搜黄色片| 可以在线观看的亚洲视频| 内地一区二区视频在线| 看黄色毛片网站| 国内精品美女久久久久久| av国产免费在线观看| 免费看美女性在线毛片视频| 一区二区三区免费毛片| 又爽又黄a免费视频| 亚洲成人精品中文字幕电影| 精品久久久久久久末码| 日韩欧美在线二视频| 老熟妇仑乱视频hdxx| 露出奶头的视频| 亚洲人成网站在线播| 十八禁国产超污无遮挡网站| 亚洲av二区三区四区| 日韩精品有码人妻一区| 国产麻豆成人av免费视频| 日韩,欧美,国产一区二区三区 | 国产精品av视频在线免费观看| 欧美一区二区国产精品久久精品| 成年人黄色毛片网站| 99热精品在线国产| 国内少妇人妻偷人精品xxx网站| 精品午夜福利在线看| 亚洲国产色片| 日本熟妇午夜| 成人国产一区最新在线观看| 国产精品美女特级片免费视频播放器| 免费在线观看日本一区| 午夜福利成人在线免费观看| 99久久精品一区二区三区| 亚洲美女视频黄频| 欧美极品一区二区三区四区| 99热只有精品国产| eeuss影院久久| av.在线天堂| 国产精品99久久久久久久久| 亚洲精品乱码久久久v下载方式| 亚洲中文字幕一区二区三区有码在线看| 麻豆精品久久久久久蜜桃| eeuss影院久久| 欧美+日韩+精品| 精品一区二区三区视频在线| 精品乱码久久久久久99久播| 伦精品一区二区三区| 免费人成视频x8x8入口观看| 久久九九热精品免费| 免费av不卡在线播放| 欧美+日韩+精品| 啦啦啦观看免费观看视频高清| 亚洲人成网站在线播| 丝袜美腿在线中文| 村上凉子中文字幕在线| 无人区码免费观看不卡| 亚洲性夜色夜夜综合| 国产一区二区三区av在线 | 国产av不卡久久| 亚洲图色成人| 国产免费一级a男人的天堂| 一边摸一边抽搐一进一小说| 天堂av国产一区二区熟女人妻| 久久精品国产亚洲网站| 1000部很黄的大片| 综合色av麻豆| 蜜桃久久精品国产亚洲av| 人妻制服诱惑在线中文字幕| 免费看美女性在线毛片视频| 亚洲人成网站高清观看| 我的女老师完整版在线观看| 最新在线观看一区二区三区| 午夜福利在线观看免费完整高清在 | 亚洲无线在线观看| 亚洲avbb在线观看| 国产精品久久久久久亚洲av鲁大| 免费电影在线观看免费观看| 深夜精品福利| 欧美日韩中文字幕国产精品一区二区三区| 99久久精品国产国产毛片| 国产大屁股一区二区在线视频| 国产精品亚洲美女久久久| 亚洲成人久久性| 麻豆国产97在线/欧美| 美女cb高潮喷水在线观看| 精品午夜福利视频在线观看一区| 老师上课跳d突然被开到最大视频| 中文字幕高清在线视频| 全区人妻精品视频| 亚洲自拍偷在线| 97超视频在线观看视频| 国产老妇女一区| 国产爱豆传媒在线观看| 色综合亚洲欧美另类图片| 日日干狠狠操夜夜爽| 精品欧美国产一区二区三| 别揉我奶头 嗯啊视频| 麻豆av噜噜一区二区三区| 国产在线精品亚洲第一网站| 女同久久另类99精品国产91| 国产一区二区在线观看日韩| 欧美性感艳星| 男人和女人高潮做爰伦理| 少妇熟女aⅴ在线视频| 亚洲欧美清纯卡通| 亚洲在线自拍视频| 少妇被粗大猛烈的视频| 亚洲人与动物交配视频| 网址你懂的国产日韩在线| a级毛片a级免费在线| 国产aⅴ精品一区二区三区波| 久久欧美精品欧美久久欧美| 欧美丝袜亚洲另类 | 黄片wwwwww| 午夜福利视频1000在线观看| 欧美绝顶高潮抽搐喷水| 国产男人的电影天堂91| 国产精品伦人一区二区| 在线观看舔阴道视频| 国产人妻一区二区三区在| 久久久久久久久久久丰满 | 91午夜精品亚洲一区二区三区 | 日韩中字成人| 亚洲乱码一区二区免费版| 美女xxoo啪啪120秒动态图| 性色avwww在线观看| 别揉我奶头~嗯~啊~动态视频| 性欧美人与动物交配| 欧美高清成人免费视频www| 国产乱人伦免费视频| 中文字幕av成人在线电影| 久久久精品欧美日韩精品| 亚洲一区高清亚洲精品| 亚洲精华国产精华液的使用体验 | 色噜噜av男人的天堂激情| av视频在线观看入口| 欧美xxxx性猛交bbbb| 日韩一区二区视频免费看| 亚洲成人中文字幕在线播放| 悠悠久久av| 色在线成人网| 别揉我奶头~嗯~啊~动态视频| 亚洲精品一卡2卡三卡4卡5卡| 舔av片在线| 国产av麻豆久久久久久久| 国产老妇女一区| 噜噜噜噜噜久久久久久91| 国产久久久一区二区三区| 99久久久亚洲精品蜜臀av| 嫩草影院新地址| 亚洲在线自拍视频| 搡女人真爽免费视频火全软件 | 国产精品国产三级国产av玫瑰| 午夜激情福利司机影院| av在线天堂中文字幕| 国产av麻豆久久久久久久| 国产亚洲91精品色在线| 黄色丝袜av网址大全| 精华霜和精华液先用哪个| 最近在线观看免费完整版| 亚洲专区国产一区二区| 91在线精品国自产拍蜜月| 国产欧美日韩精品一区二区| 欧美黑人欧美精品刺激| 真人做人爱边吃奶动态| 亚洲精品色激情综合| 欧美日韩亚洲国产一区二区在线观看| 午夜福利在线在线| 亚洲人与动物交配视频| 亚洲成人中文字幕在线播放| 午夜激情福利司机影院| 国产高清视频在线播放一区| 最近在线观看免费完整版| 国产毛片a区久久久久| or卡值多少钱| 日韩一区二区视频免费看| 九九久久精品国产亚洲av麻豆| 久久99热6这里只有精品| 欧美区成人在线视频| 国产私拍福利视频在线观看| 亚洲三级黄色毛片| 深夜精品福利| 级片在线观看| 亚洲内射少妇av| 亚洲av成人精品一区久久| 成年女人永久免费观看视频| 亚洲三级黄色毛片| 九九久久精品国产亚洲av麻豆| 色尼玛亚洲综合影院| 人妻夜夜爽99麻豆av| 免费在线观看成人毛片| 亚洲专区国产一区二区| 国产精品爽爽va在线观看网站| 干丝袜人妻中文字幕| 欧美高清成人免费视频www| 国产精品av视频在线免费观看| 久久午夜亚洲精品久久| 18+在线观看网站| 国产女主播在线喷水免费视频网站 | a级一级毛片免费在线观看| 少妇被粗大猛烈的视频| 在现免费观看毛片| 午夜久久久久精精品| 日韩精品青青久久久久久| 69人妻影院| 成人精品一区二区免费| 国产蜜桃级精品一区二区三区| 成人一区二区视频在线观看| 亚洲av成人av| 色5月婷婷丁香| 久久久精品欧美日韩精品| 日日摸夜夜添夜夜添小说| 免费观看人在逋| 中文资源天堂在线| 亚洲性夜色夜夜综合| 亚洲专区国产一区二区| 亚洲精品影视一区二区三区av| 又黄又爽又免费观看的视频| 国产精品精品国产色婷婷| 又爽又黄a免费视频| 99热网站在线观看| 亚洲久久久久久中文字幕| www日本黄色视频网| 成年人黄色毛片网站| 午夜福利在线在线| 人妻少妇偷人精品九色| 亚洲一区二区三区色噜噜| 亚洲va在线va天堂va国产| 亚洲电影在线观看av| 麻豆成人午夜福利视频| 我的老师免费观看完整版| 亚洲五月天丁香| 日日摸夜夜添夜夜添小说| 精品久久久久久久久亚洲 | 亚洲av成人精品一区久久| 97超视频在线观看视频| av黄色大香蕉| 狂野欧美激情性xxxx在线观看| 波多野结衣巨乳人妻| 亚洲狠狠婷婷综合久久图片| 乱码一卡2卡4卡精品| 嫩草影院精品99| 国产亚洲精品av在线| 国产精品精品国产色婷婷| 亚洲成av人片在线播放无| 久久久久九九精品影院| 在线a可以看的网站| 亚洲欧美清纯卡通| 国产 一区精品| 一级av片app| 日本黄色视频三级网站网址| 国产精品久久视频播放| 国产老妇女一区| 午夜激情欧美在线| 欧美日本亚洲视频在线播放| 色视频www国产| 精品福利观看| 在线观看午夜福利视频| 午夜福利在线观看免费完整高清在 | 99久久精品国产国产毛片| 老司机深夜福利视频在线观看| 给我免费播放毛片高清在线观看| 亚洲中文字幕日韩| 日韩亚洲欧美综合| 国产精品综合久久久久久久免费| 亚洲avbb在线观看| 国产精品一及| 午夜激情欧美在线| 一级黄色大片毛片| 国产av不卡久久| 久久精品国产99精品国产亚洲性色| 日韩在线高清观看一区二区三区 | 亚洲精品久久国产高清桃花| 亚洲在线自拍视频| 久久欧美精品欧美久久欧美| 一夜夜www| 九色国产91popny在线| 欧美又色又爽又黄视频| 国产精品女同一区二区软件 | 精品人妻一区二区三区麻豆 | 国产亚洲精品久久久久久毛片|